Ilkka Kantola
 Professor; Head of Medical Division, Turku university Hospital

Docent,  Faculty of Medicine (University of Turku) ilkkan@utu.fi ORCID identifier: https://orcid.org/0000-0002-6228-522X CURRICULUM VITAE OF ILKKA KANTOLA041117.pdf

Publications

  

  

  

2 of 10

  

  

  

---

• Development and clinical validation of a miniaturized finger probe for bedside hemodynamic monitoring  (2023)  
  • iScience
   Panula Tuukka, Sirkiä Jukka-Pekka, Koivisto Tero, Pänkäälä Mikko, Niiranen Teemu, Kantola Ilkka, Kaisti Matti
  (A1 Refereed original research article in a scientific journal)

  
  

• Fabryn tauti  (2023)  Reumasairaudet Kantola Ilkka
  (D2 Article in a professional compilation book)

  
  

• Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study  (2023)  
  • Journal of Medical Genetics
   Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, Linhart A, Hughes DA, Hopkin RJ, Tøndel C, Langeveld M, Giraldo P, Pisani A, Germain DP, Mehta A, Deegan PB, Molnar MJ, Ortiz D, Jovanovic A, Muriello M, Barshop BA, Kimonis V, Vujkovac B, Nowak A, Geberhiwot T, Kantola I, Knoll J, Waldek S, Nedd K, Karaa A, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Sakov A, Warnock DG
  (A1 Refereed original research article in a scientific journal)

  
  

• Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation  (2023)  
  • Open Heart
   Valtola Kati, Hedman Marja, Kantola Ilkka, Walls Susanne, Helisalmi Seppo, Maria Maleeha, Raivo Joose, Auray-Blais Christiane, Kuusisto Johanna
  (A1 Refereed original research article in a scientific journal)

  
  

• Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study  (2023)  
  • American Journal of Medical Genetics Part A
   Pietilä-Effati Päivi, Saarinen Jukka T, Löyttyniemi Eliisa, Saarenhovi Maria, Autio Reijo, Kantola Ilkka
  (A1 Refereed original research article in a scientific journal)

  
  

• Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan  (2022)  
  • Journal of Clinical Hypertension
   Danaietash Parisa, Verweij Pierre, Wang Ji-Guang, Dresser George, Kantola Ilkka, Lawrence Mary Katherine, Narkiewicz Krzysztof, Schlaich Markus, Bellet Marc
  (A1 Refereed original research article in a scientific journal)

  
  

• Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation  (2022)  
  • Molecular Genetics and Genomic Medicine
   Pietilä-Effati Päivi, Söderström Johan, Saarinen Jukka T, Löyttyniemi Eliisa, Kantola Ilkka
  (A1 Refereed original research article in a scientific journal)

  
  

• THE CHANGE IN QUALITY OF LIFE IN DRUG TREATED HYPERTENSIVE PATIENTS AFTER 10 YEARS OF ANTIHYPERTENSIVE TREATMENT  (2022)  
  • Journal of Hypertension
   Kantola Ilkka M., Kantola Taru
  (Other publication)

  
  

• The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF)  (2022)  
  • Primary Care Diabetes
   Metsärinne Kaj, Pietilä Mikko, Kantola Ilkka, Stenman Lotta K, Hätinen Olli-Pekka, Vesikansa Aino, Poussa Tuija, Niskanen Leo; STONE HF (STatus Of kidNEy disease in type 2 diabetes and heart failure in Finnish primary care) study investigators
  (A1 Refereed original research article in a scientific journal)

  
  

• Verenpainetaudin, sepelvaltimotaudin ja sydämen vajaatoiminnan lääkehoito  (2022)  Farmakologia ja toksikologia Kantola Ilkka, Mervaala Eero
  (D2 Article in a professional compilation book)